BeyondSpring (NASDAQ: BYSI) — Company Overview, News & Financial Data
BeyondSpring develops cancer therapies to improve outcomes, highlighted by its Plinabulin drug for chemotherapy-induced neutropenia.
BeyondSpring
BeyondSpring (NASDAQ:BYSI) is a global biopharmaceutical company focused on the development of innovative cancer therapies. It is known for its work on creating advanced treatments aiming to improve outcomes for patients facing serious oncological challenges. The company's flagship project involves the drug Plinabulin, which is designed to prevent chemotherapy-induced neutropenia (CIN) - a common and serious side effect of cancer treatment. BeyondSpring is committed to advancing its pipeline of novel medications through clinical trials with the goal of bringing new therapies to market. The company's efforts are driven by a dedication to enhancing the lives of those affected by cancer through the delivery of effective and safer treatment options.
Snapshot
Operations
Products and/or services of BeyondSpring
- Plinabulin, a novel cancer therapy with multiple indications including treatment for chemotherapy-induced neutropenia and non-small cell lung cancer.
- BPI-002, an oral small molecule for enhancing T cell activation to boost cancer immunotherapy effectiveness.
- BPI-003, a novel inhibitor targeting a key cancer cell growth and survival pathway.
- A pipeline of early-stage oncology assets exploring innovative approaches to cancer treatment.
- Collaborations on combination therapies to enhance the efficacy of current cancer treatment regimens.
- Research and development services related to oncology drug discovery for partner pharmaceutical and biotechnology companies.
BeyondSpring executive team
- Dr. Lan Huang Ph.D.Co-Founder, Chairman & CEO
- Dr. June Lu Ph.D.Chief Scientific Officer
- Ms. Joy JiaVP of Finance
- Stephen KilmerHead of Investor Relations
- Dr. John Mao Ph.D.Senior Vice President of Development